Nectar Lifesciences Ltd (NSE: NECLIFE, BSE: 532649) is a Chandigarh-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹201 Cr, it ranks #2,643 by market cap among the 6,197 Indian listed companies on FinBizNet, and #55 of 86 in Medicinal Chemicals and Botanical Products. At ₹10.60 (as of 16 Nov 2026), the share price is 52.7% below its 52-week high of ₹22.40 and 14.0% above its 52-week low of ₹9.30. The share price is down 27.4% over one year and down 6.0% over three months.
| Current Price | ₹10.60 |
|---|---|
| Market Cap | ₹201 Cr |
| NSE Symbol | NECLIFE |
| BSE Code | 532649 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | -7.46% |
| Return on Assets | -5.21% |
| 52-Week Range | ₹9.30 – ₹22.40 |
| 1-Year Price Change | -27.4% |
| 3-Month Price Change | -6.0% |
| Beta (1Y) | 0.9 |
| Dividend Yield | 0.00% |
| Headquarters | Chandigarh |
| Website | www.neclife.com |
| Revenue | ₹0 Cr |
|---|---|
| Net Profit | ₹3 Cr |
| Net Margin | 27200.0% |
| EPS (Basic) | ₹0.18 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Nectar Lifesciences Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.8% from ₹5 Cr in Q2 FY26 and up 0.0% from ₹0 Cr in Q1 FY27. It posted a net profit of ₹3 Cr for the quarter, against a net loss of ₹176 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹0 Cr (Q4 FY26) to ₹431 Cr (Q4 FY25). The company reported a net loss in 5 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹0 Cr | ₹3 Cr | 27200.0% |
| Q1 FY27 | ₹0 Cr | −₹15 Cr | −154000.0% |
| Q4 FY26 | ₹0 Cr | −₹68 Cr | — |
| Q3 FY26 | ₹0 Cr | ₹14 Cr | — |
| Q2 FY26 | ₹5 Cr | −₹176 Cr | −3520.2% |
| Q1 FY26 | ₹281 Cr | −₹63 Cr | −22.5% |
| Q4 FY25 | ₹431 Cr | −₹130 Cr | −30.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.84% of Nectar Lifesciences Ltd's shares as of Sept 2026, against 44.91% in Dec 2025 (+6.93 percentage points). Delivery averaged 76.1% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Nectar Lifesciences Limited manufactures, distributes, markets and sells pharmaceutical products in India and internationally. The company offers cephalosporins, includes pharmaceutical ingredients and intermediates comprising cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also provides contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins. In addition, the company offers menthol and pearl capsules. Nectar Lifesciences Limited was incorporated in 1995 and is headquartered in Chandigarh, India.
1. Pharmaceutical Business-This segment operates as an integrated pharmaceutical company. It manufactures active pharmaceutical ingredients and formulations.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Nectar Lifesciences Ltd | ₹201 Cr | n/m | -7.46% | ₹0 Cr | -27.4% |
Listed by market capitalisation. Ratios are shown for context only.
Nectar Lifesciences Ltd is trading at ₹10.60, with a market capitalisation of ₹201 Cr.
Nectar Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Nectar Lifesciences Ltd has a return on equity of -7.46%.
Nectar Lifesciences Ltd is listed on the NSE under the symbol NECLIFE and on the BSE under the scrip code 532649.
Nectar Lifesciences Ltd's share price is down 27.4% over one year and down 6.0% over three months. Its 52-week range is ₹9.30 to ₹22.40.
In Q2 FY27, Nectar Lifesciences Ltd reported revenue of ₹0 Cr and net profit of ₹3 Cr, with basic EPS of ₹0.18 (consolidated, parsed from the company's exchange filing).
Nectar Lifesciences Ltd reported revenue of ₹0 Cr in Q2 FY27, down 99.8% from ₹5 Cr in Q2 FY26 and up 0.0% from ₹0 Cr in Q1 FY27.
Promoters held 51.84% of Nectar Lifesciences Ltd's shares as of Sept 2026, against 44.91% in Dec 2025 (+6.93 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.